Learn The BasicsThe prognosis of Thymine Kinase 2 deficiency (TK2d), an ultra-rare genetic disease caused by a mutation in the TK2 gene, mainly depends on the type of disease.
Based on the age of symptom onset, TK2d can be grouped into three subtypes: early/infantile-onset, childhood-onset and late-onset.
Prognosis by disease type
In early- or infantile-onset TK2d, the symptoms of the disease usually appear before the patient is age 1 and include severe muscle weakness affecting the arms and legs as well as the muscles used for swallowing and breathing. Patients with this type of disease usually have a prognosis of 1 or 2 years from symptom onset and the cause of death is often respiratory failure.
Patients with childhood-onset TK2d first show the symptoms of the disease when they are between ages 1 and 12. The disease is less severe and progresses more slowly in these patients. Children usually need a wheelchair for mobility by the time they are 10 years old due to muscle weakness. Death may occur around 13 years after the onset of symptoms, typically due to respiratory failure caused by respiratory muscle weakness.
Finally, patients with late-onset disease, whose symptoms typically develop after age 12, can live up to 20 to 30 years from the time of first symptom onset. These patients usually maintain the ability to walk, though they may need assistive devices for support. Like with the two other types of disease, death often occurs due to respiratory failure.
Long-term outlook with current treatments and supportive care
Patients with TK2d deficiency often require ongoing medical treatment and care as well as supportive devices, which can improve the long-term outlook of the disease.
There is currently no cure for TK2d, so available treatment options focus on reducing disease symptoms and improving patients’ quality of life.
Rehabilitation therapy for patients may include physical therapy to maintain muscle strength and function, occupational therapy to maintain independence and learn how to use adaptive devices, respiratory therapy to strengthen muscles used for breathing, clear mucus and reduce the risk of lung infections and speech therapy to improve speech and swallowing difficulties.
Supportive devices that patients with TK2d include walking aids like canes, walkers and wheelchairs, and ventilators to aid with breathing.
Additionally, the U.S. Food and Drug Administration approved a therapy in November 2025 to treat patients who showed TK2d symptoms before the age of 12.
Called nucleoside therapy, the treatment aims to provide the body with nucleosides that it is not able to recycle by itself due to the deficiency of the TK2 enzyme. These nucleosides are essential for the maintenance and replication of the DNA inside the mitochondria, the power plants of cells.
Research has shown that nucleoside therapy may improve survival and stabilize or even improve motor function, respiratory function and feeding ability in patients with TK2d.
The therapy may also be able to stop the progression of the disease in patients with infantile-onset TK2d.